Clinical trials: Experimental
Healthy
Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants
A study to investigate the safety and reactogenicity of MT-5625 independently in adults aged 18-35 years, toddlers ages 12-24 months, and infants aged 6-10 weeks
- Trial name
- NCT03507738
- Testing
- MT-5625 low dose, MT-5625 middle dose, MT-5625 high dose
- Where
- 2 sites in Australia, South Africa
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
HIV Infection
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure
This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy…
- Trial name
- NCT00038506
- Testing
- abacavir/lamivudine/zidovudine, tenofovir
- Where
- 27 sites in United States
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare
Accommodation
Investigational Study of Accommodation Triggering and Control to Allow for the Performance of Refraction Measurements
An investigational study in the control of the user's accommodative state via visual stimuli.
- Trial name
- NCT03957408
- Testing
- Visual Stimuli
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EyeQue Corp.
Breast Cancer, Melanoma
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary…
- Trial name
- NCT01106040
- Testing
- Lymphoseek
- Where
- 8 sites in United States
- Volunteers
- 163 people
- Sponsor
- Navidea Biopharmaceuticals
Glioblastoma
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
VXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01
- Trial name
- NCT02718443
- Testing
- VXM01
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Vaximm GmbH
Skin Aging
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
This research study will test how well a light therapy mask works for women with mild to moderate hyperpigmentation (brown spots) and moderate to severe facial wrinkles, as compared to a "sham" or inactive investigational light…
- Trial name
- NCT03312543
- Testing
- Active Mask
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Respiratory Tract Infections
Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens
This first-in-man (FIM) phase I study will evaluate the acute safety, tolerability, and acceptability of the investigational RD19 device among 25 healthy volunteers between the age of 18 and 45.
- Trial name
- NCT04557826
- Testing
- RD19
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- EmitBio Inc.
Respiratory Syncytial Virus Infections
A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)
The purpose of the study is to evaluate the immunogenicity and safety of a single dose of investigational RSVPreF3 OA vaccine in Indian older adults 60 years of age (YOA) and above and Indian adults 50-59 YOA at increased risk of…
- Trial name
- NCT06614725
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 14 sites in India
- Volunteers
- 751 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Diabetes
Performance of an Investigational Blood Glucose Monitoring System
The purpose of this study was to demonstrate that untrained subjects who have diabetes can operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose results.
- Trial name
- NCT01824355
- Testing
- Ninja 3 PLUS Investigational BG Monitoring System
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Ascensia Diabetes Care
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Trial name
- NCT03693378
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 1,349 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Renal Cell Carcinoma
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 [KLH-FITC] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination…
- Trial name
- NCT00485563
- Testing
- EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Endocyte
HIV Infections
Drug Exposure Registry for GSK2248761, an Investigational NNRTI
The World Health Organization has estimated that as many as 10% of the population worldwide may at some point experience at least one seizure. The percentage with active epilepsy is from 0.4% to 1%.
- Trial name
- NCT01458132
- Volunteers
- 19 people
- Sponsor
- ViiV Healthcare
Healthy
A Study of 3 Investigational Products on the Microbiome and Scalp Attributes in Children With Curly Hair
The purpose of this study is to evaluate the topical safety (tolerability/acceptability) of a kit of cosmetic products (shampoo, conditioner, and combing cream), the presence of residues on the scalp through visual assessment and…
- Trial name
- NCT05123911
- Testing
- Investigational Conditioner, Investigational Combing Cream
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
HIV Infections, Acquired Immunodeficiency Syndrome
Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
This study will investigate the safety and efficacy of different doses of an investigational drug (MK0518) as a therapy for HIV-infected patients failing current antiretroviral therapies.
- Trial name
- NCT00105157
- Testing
- Comparator: MK0518, MK0518
- Volunteers
- 179 people
- Sponsor
- Merck Sharp & Dohme LLC
Functional Constipation, Healthy
Evaluating Efficacy of Investigational Products on Spontaneous Bowel Movements in Healthy People With ≤ 3 Complete Weekly Spontaneous Bowel Movements
Low and High doses of Actazin and Livaux will be compared against a control formula and placebo to evaluate how each investigational study product effects complete spontaneous bowel movements in healthy adults that currently…
- Trial name
- NCT03462199
- Testing
- Actazin (green kiwi powder) High Dose, Actazin (green kiwi powder) Low Dose, Control Formula (Actazin green kiwi powder + PreticX prebiotic)
- Where
- Canada
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- AIDP, Inc.
Pain
Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid
Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause.
- Trial name
- NCT01449487
- Testing
- PPC-5650
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Aros Pharma ApS
Herpes Zoster, Herpes Zoster-related Complications
A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)
This study will evaluate the safety and immunogenicity of a heat-treated VZV vaccine in autologous or allogeneic hematopoietic cell transplant (HCT) recipients, human immunodeficiency virus (HIV)-infected participants with a…
- Trial name
- NCT00535236
- Testing
- V212
- Volunteers
- 341 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
The primary purpose of the study is to investigate safety and tolerability following single and multiple ascending subcutaneous (SC) and intramuscular (IM) doses of capsid inhibitors in healthy participants.
- Trial name
- NCT06012136
- Testing
- VH4004280, VH4011499
- Where
- 2 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis B
A Study of the Immune Response to Heplisav in Healthy Older Adults
This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.
- Trial name
- NCT01999699
- Testing
- HEPLISAV
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation